skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension

Review

(3837) Views  (802) Full article downloads

Authors: Kari E Roberts, Ioana R Preston

Published Date March 2009 Volume 2009:3 Pages 111 - 118
DOI: http://dx.doi.org/10.2147/DDDT.S3786

Kari E Roberts, Ioana R Preston

Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USA

Abstract: Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH). Bench to bedside scientific research has clearly shown that endothelin-1 (ET-1) is over-expressed in several forms of pulmonary vascular disease and plays an important pathogenetic role in the development and progression of PAH. Oral endothelin receptor antagonists (ERAs) have been shown to improve exercise capacity, functional status, pulmonary hemodynamics, and delay the time to clinical worsening in several randomized placebo-controlled trials. Bosentan, the first oral ERA, was approved in 2001 and since that time it has established a strong record of safety and efficacy in PAH. More recently, two additional ERAs, ambrisentan and sitaxsentan, have been approved for use. The objective of this review is to evaluate the available evidence supporting the efficacy, pharmacology, safety and tolerability, and patient-focused perspectives for bosentan, the first approved ERA for PAH. Ongoing and forthcoming randomized trials are also highlighted including the application of bosentan in combination with other PAH therapies.

Keywords: bosentan, endothelin receptor antagonists, pulmonary arterial hypertension

 




 

Other articles by Dr Ioana Preston



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Optimizing supercritical antisolvent process parameters to minimize the particle size of paracetamol nanoencapsulated in L-polylactide
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University